BRIEF-Aurinia announces that voclosporin achieves endpoints in its Phase IIB Aura-LV Study

Thu Sep 29, 2016 4:59pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Sept 29 (Reuters) - Aurinia Pharmaceuticals Inc

* Comprehensive mortality review concludes deaths in aura-lv study appear to be unrelated to study drug and consistent with complications of ln

* Announces that Voclosporin achieves primary and all pre-specified secondary endpoints in its phase IIB Aura-LV study for Lupus Nephritis (ln) Source text for Eikon: Further company coverage: